The role of inflammation in DME

Article

The level of various inflammatory factors in the vitreous fluid is a significant factor in the severity of diabetic macular oedema (DME), according to study results published in the January issue of Ophthalmology.

The level of various inflammatory factors in the vitreous fluid is a significant factor in the severity of diabetic macular oedema (DME), according to study results published in the January issue of Ophthalmology.

Hideharu Funatsu, MD of the Tokyo Women's Medical University, Japan and colleagues conducted a retrospective case-control study of DME patients (n=53), patients with non-diabetic ocular disease (n=15) and diabetic patients who were free of retinopathy (n=8). The team examined samples of the vitreous fluid to determine levels of inflammatory factors, specifically vascular endothelial growth factor (VEGF), intercellular adhesion molecule (ICAM)-1, interleukin (IL)-6, monocyte chemotactic protein (MCP)-1, and pigment epithelium-derived factor (PEDF).

The researchers found that DME patients demonstrated significantly higher levels of VEGF, ICAM-1, IL-6 and MCP-1 when compared with other patient groups, although the level of PEDF was significantly lower in the vitreous of DME patients when compared with other patient groups. In addition, the levels of each of these inflammatory factors in the vitreous were associated with the thickness of the retina at the central fovea. VEGF and ICAM-1 had a greater influence on the severity of DME than IL-6, MCP-1 or PEDF.

The team concluded that the level of these inflammatory factors - particularly VEGF and ICAM-1 - in the vitreous correlate significantly to the permeability of the retina and the severity of DME.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.